January 1, 2007 (Santa Clara, CA)

INDEC Systems, Inc. (INDEC, President: Mr. Kal Hubler, headquarters Santa Clara, California, U.S.A., www.indecsystems.com) has formed a strategic partnership with AntiCancer, Inc. (CEO: Dr. Robert M. Hoffman, headquarters: San Diego, California, U.S.A., www.anticancer.com). Starting in February, 2007, INDEC will introduce its new FluorVivo^TM fluorescence imaging systems, especially suited to the unique opportunities presented by AntiCancer's proprietary fluorescent-protein-based small-animal technologies, including their mouse models of cancer, MetaMouse^® and AngioMouse^®.

This partnership will bring powerful in vivo technologies to a broad range of laboratories, from those doing basic to pre-clinical research. The partners expect that the product’s unprecedented ease of use and cost-effectiveness will greatly expand the acceptance and use of these methods.

INDEC will display FluorVivo^TM, its first in vivo molecular imaging system, together with other products for fluorescence imaging, in its booth at the Centennial Meeting of the American Association of Cancer Research (President. Geoffrey M. Wahl, Ph.D.), to be held in Los Angeles, California from April 14 to April 18, 2007.

Background

Molecular imaging enables visualization of cellular and molecular events within living organisms and is an important tool for understanding the mechanisms of disease. Fluorescence imaging is increasingly used in cancer and other biomedical research; and plays an important role in translational research – developing clinical applications from basic science.

INDEC has designed, implemented, and brought to market a broad range of software-intensive digital instruments for the acquisition, visualization and analysis of biological and medical data. Each of INDEC’s products has been designed for clinicians and researchers working with specialized instruments, including fluorescence microscopes, scientific digital cameras, and systems for intra-vascular ultrasound (IVUS).

AntiCancer, founded in 1984, has developed the leading mouse models of cancer including MetaMouse^® and AngioMouse^®. These models are made imageable with AntiCancer’s OncoBrite^® technology using fluorescent proteins. AntiCancer is also developing new cancer drugs based on genetic engineering that target cancer-specific metabolic defects. The company is also developing recombinant-enzyme-based diagnostics for cancer and cardiovascular disease. AntiCancer also offers the Histoculture Drug Response Assay (HDRA) for individualized cancer treatment. AntiCancer pioneered hair follicle gene therapy and is also pioneering the use of pluripotent hair-follicle stem cells for chemotherapy-induced hair loss and regenerative medicine for neurological and other diseases.